Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

P. Moreau, D. Joshua, WJ. Chng, A. Palumbo, H. Goldschmidt, R. Hájek, T. Facon, H. Ludwig, L. Pour, R. Niesvizky, A. Oriol, L. Rosiñol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, HH. Gillenwater, N. Mohamed, S. Aggarwal, S....

. 2017 ; 31 (1) : 115-122. [pub] 20160704

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc17031533
E-resources Online Full text

NLK ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Nursing & Allied Health Database (ProQuest) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Public Health Database (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 27491641
DOI 10.1038/leu.2016.186
Knihovny.cz E-resources

The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031533
003      
CZ-PrNML
005      
20171025115529.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/leu.2016.186 $2 doi
035    __
$a (PubMed)27491641
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Moreau, P $u University of Nantes, Nantes, France.
245    10
$a Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study / $c P. Moreau, D. Joshua, WJ. Chng, A. Palumbo, H. Goldschmidt, R. Hájek, T. Facon, H. Ludwig, L. Pour, R. Niesvizky, A. Oriol, L. Rosiñol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, HH. Gillenwater, N. Mohamed, S. Aggarwal, S. Feng, MA. Dimopoulos,
520    9_
$a The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bortezomib $x aplikace a dávkování $x terapeutické užití $7 D000069286
650    _2
$a dexamethason $x aplikace a dávkování $x terapeutické užití $7 D003907
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    _2
$a oligopeptidy $x aplikace a dávkování $x terapeutické užití $7 D009842
650    _2
$a recidiva $7 D012008
650    _2
$a záchranná terapie $x metody $x mortalita $7 D016879
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Joshua, D $u Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
700    1_
$a Chng, W-J $u National University Cancer Institute, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
700    1_
$a Palumbo, A $u University of Torino, Torino, Italy.
700    1_
$a Goldschmidt, H $u Heidelberg Medical University, Heidelberg, Germany.
700    1_
$a Hájek, R $u University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Facon, T $u CHRU Lille Hôpital Claude Huriez, Lille, France.
700    1_
$a Ludwig, H $u Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
700    1_
$a Pour, L $u University Hospital Brno, Brno, Czech Republic.
700    1_
$a Niesvizky, R $u Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
700    1_
$a Oriol, A $u Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
700    1_
$a Rosiñol, L $u Hospital Clínic de Barcelona, Barcelona, Spain.
700    1_
$a Suvorov, A $u Hematological Department, First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia.
700    1_
$a Gaidano, G $u Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
700    1_
$a Pika, T $u Department of Hematooncology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Weisel, K $u Universitätsklinikum Tübingen, Tübingen, Germany.
700    1_
$a Goranova-Marinova, V $u University Multiprofile Hospital for Active Treatment 'Sv. Georgi' and Medical University, Plovdiv, Bulgaria.
700    1_
$a Gillenwater, H H $u Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
700    1_
$a Mohamed, N $u Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
700    1_
$a Aggarwal, S $u Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA. $7 gn_A_00002140
700    1_
$a Feng, S $u Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
700    1_
$a Dimopoulos, M A $u National and Kapodistrian University of Athens, Athens, Greece.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 31, č. 1 (2017), s. 115-122
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27491641 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025115611 $b ABA008
999    __
$a ok $b bmc $g 1255126 $s 992560
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 31 $c 1 $d 115-122 $e 20160704 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20171025
Back

Find record

Citation metrics

Archiving options